Re: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
- From: William Wagner <not-to-here-williamwag@xxxxxxxxx>
- Date: Thu, 24 May 2007 11:11:27 -0400
In article <1180016201.137033.126960@xxxxxxxxxxxxxxxxxxxxxxxxxxxx>,
MarilynMann <mannm@xxxxxxxxxxx> wrote:
The Lancet has an editorial on its website discussing the
controversy: http://multimedia.thelancet.com/pdf/rosiglitazone_editorial.pdf.
The unsigned editorial suggests that "the FDA, physicians, and
patients can reasonably await the results of RECORD, a phase III trial
designed specifically to study cardiovascular outcomes."
Asked to comment, Journal Watch Cardiology Editor-in-Chief Harlan M.
Krumholz wrote: "Why would you wait when Avandia has never been shown
to avert events or save lives? And now that there is evidence of
potential harm - and there are alternative meds - it seems to me that
the pressure is on the company to show that it is safe and effective."
Marilyn
Just an observation.
But it seems medicine as a business has eclipsed medicine as an art. I
find more info first in the Wall Street Journal than any where else
besides SMC :)).
So the question becomes what is of import return on investment or the
health of the people. I guess this is a call for a more socialized
human centered approach for fixing our ill's. Cause and remedies and
preventive issues need clarity need a champion.
Bill who wonders if Avandia user's will ever see "Why would you wait
when Avandia has never been shown to avert events or save lives? "
--
S Jersey USA Zone 5 Shade
http://www.ocutech.com/ High tech Vison aid
This article is posted under fair use rules in accordance with
Title 17 U.S.C. Section 107, and is strictly for the educational
and informative purposes. This material is distributed without profit.
.
- References:
- Prev by Date: Re: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
- Next by Date: Cholestrol and weight
- Previous by thread: Re: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
- Next by thread: Re: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
- Index(es):
Relevant Pages
|